UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Learn the scenarios where index funds outperform target date funds, with emphasis on fees, control, and asset allocation flexibility.
26,348 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
United Airlines faces near term pressure from higher fuel costs, yet the Street remains optimistic with a consensus t...
KeyBanc lowers its price target for On Holding AG to $43, citing tariff exposure that weighs on margins, even as the ...
ConocoPhillips faces a clash between a wave of Buy ratings and a cautious price target, as crude markets rebound and ...
As brookfield corp's next earnings approaches, investors weigh how the company will navigate its diverse asset mix. T...
Investors are weighing three dividend strategies that can yield $7,500 a month. Each path offers a different balance ...
When the market rattles, some stocks prove more durable than others. This guide highlights two steady performers and ...
A resurfaced teen photo sparked online backlash for Hudson Williams, highlighting how reputational events can ripple ...
The SpaceX IPO dominates chatter, but you don’t have to wait to gain space exposure. Here are three space stocks with...
A surprise visit from a football star turns a school yard into a money lesson. This article breaks down practical bud...
When relationships hit turbulence in the public eye, money often becomes the quiet crisis. This article translates th...
A renowned artist and philanthropist reveals a different dream: winemaking. This article turns that tale into practic...